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Systemic cyclosporin A and tacrolimus are effective
treatments for psoriasis. Cyclosporin A and tacro-
limus block T cell activation by inhibiting the phos-
phatase calcineurin and preventing translocation
from the cytoplasm to the nucleus of the transcrip-
tion factor nuclear factor of activated T cells
(NFAT). Inhibition of T cell activation is thought to
account for their therapeutic action in psoriasis. We
investigated whether nonimmune cells in human
skin express calcineurin and NFAT1 and whether
cyclosporin A and tacrolimus block activation of cal-
cineurin/NFAT in epidermal keratinocytes. The
expression patterns of the principal components of
calcineurin/NFAT signaling pathway in normal
human skin and psoriasis were determined by immu-
nohistochemistry. We assessed calcineurin/NFAT
activation in cultured keratinocytes by measuring the
degree of nuclear localization of calcineurin and
NFAT1 using immuno¯uorescence/confocal micro-
scopy and assessed if cyclosporin A and tacrolimus
blocked nuclear translocation of these proteins. A
variety of cell types in normal and psoriatic skin
expressed calcineurin and NFAT1, but expression
was particularly prominent in keratinocytes. The
principal cyclosporin A and tacrolimus binding
proteins cyclophilin A and FKBP12 were also
expressed by keratinocytes and nonimmune cells in
skin. NFAT1 was predominantly nuclear in normal
basal epidermal keratinocytes. Increased nuclear
localization of NFAT1 was observed in suprabasal
keratinocytes within lesional and to a lesser extent
nonlesional psoriatic epidermis compared to normal
skin (p = 0.001 and p = 0.03, respectively), suggest-
ing increased activation of calcineurin in psoriatic
epidermal keratinocytes. Agonists that induce kerati-
nocyte differentiation, speci®cally 12±0-tetradeca-
noyl-phorbol-13-acetate (TPA) plus ionomycin,
TPA, and raised extracellular calcium, induced
nuclear translocation of NFAT1 and calcineurin in
keratinocytes that was inhibited by pretreatment
with cyclosporin A or tacrolimus. In contrast in
human dermal ®broblasts, TPA plus ionomycin or
TPA did not signi®cantly alter the proportion of
nuclear-associated NFAT1. These data provide the
®rst evidence that calcineurin is functionally active in
human keratinocytes inducing nuclear translocation
of NFAT1 and also indicate that regulation of
NFAT1 nuclear translocation in skin is cell type spe-
ci®c. Inhibition of this pathway in epidermal kerati-
nocytes may account, in part, for the therapeutic
effect of cyclosporin A and tacrolimus in skin dis-
eases such as psoriasis. Key words: calcium/cell differen-
tiation/immunophilin/signal transduction/tacrolimus. J
Invest Dermatol 118:779±788, 2002
P
soriasis is a chronic, disabling skin disease, which affects
approximately 2% of the population in Western
countries. Psoriatic plaques are characterized by in-
creased keratinocyte proliferation leading to epidermal
hyperplasia, abnormal keratinocyte differentiation, in-
®ltration of epidermis and dermis by activated lymphocytes and
neutrophils, and tortuous and dilated upper dermal blood vessels.
Systemic cyclosporin A (CsA) and tacrolimus are effective
treatments for psoriasis (Ellis et al, 1986; Jegasothy et al, 1992).
Their widespread use is, however, limited by side-effects, (Powles
et al, 1998).
CsA and tacrolimus are immunosuppressive drugs that inhibit T
cell activation through well-characterized pathways, established
through biochemical, genetic, and crystallographic studies (Rao
et al, 1997). Speci®cally, CsA and tacrolimus bind to intracellular
proteins, principally cyclophilin A and FKBP12, respectively, and
thereby inhibit the phosphatase calcineurin. This leads to an
increased phosphorylation of calcineurin substrates, particularly the
family of nuclear factor of activated T cells (NFAT) nuclear
transcription factors, preventing translocation of NFAT to the
nucleus. As NFAT is essential for interleukin-2 (IL-2) gene
transcription, IL-2 production and T cell activation is inhibited
(Rao et al, 1997). In addition to their role in immune activation,
calcineurin and members of the NFAT family are known to be
expressed relatively selectively in a variety of nonimmune cells
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including heart, muscle, and brain (Rao et al, 1997; Chin et al,
1998; Molkentin et al, 1998; Graef et al, 1999) and exert diverse
effects such as regulation of cardiac hypertrophy, blood vessel
assembly, muscle differentiation, and memory formation (Rao et al,
1997; Chin et al, 1998; Aramburu et al, 2000; Graef et al, 2001;
Malleret et al, 2001).
The ef®cacy of CsA and tacrolimus has been used as a powerful
argument to support the fundamental role of T cells in the
pathogenesis of psoriasis. Several studies indicate, however, that
CsA exerts direct effects in skin independent of its action on T cells.
For example, CsA and tacrolimus inhibit proliferation of cultured
keratinocytes at therapeutically relevant concentrations (Fisher et al,
1988; Cooper et al, 1992), although whether CsA exerts an effect
on human keratinocyte proliferation in vivo remains controversial.
In mouse skin, however, topical CsA inhibits 12-O-tetradecanoyl-
phorbol-13-acetate (TPA) induced epidermal hyperplasia, as well as
leukocyte in®ltration and keratinocyte-derived transglutaminase
activity (Gupta et al, 1989). Furthermore, CsA inhibits epidermal
proliferation in nude mice (Ramirez-Bosca et al, 1990) and inhibits
TPA-induced in¯ammation in SCID mice, in the absence of
functioning T cells (Reynolds et al, 1998). CsA and tacrolimus both
induce hair growth (Watanabe et al, 1991; Taylor et al, 1993;
Yamamoto-Hino et al, 1994) and topical tacrolimus stimulates hair
growth in SCID mice (Yamamoto-Hino et al, 1994). CsA also
inhibits antigen presentation by Langerhans cells (Furue and Katz,
1988) and inhibits neutrophil chemotaxis (Pigatto et al, 1990). If
CsA and tacrolimus are having local pharmacologic effects in skin,
independent of T cells, this may have important implications for
our understanding of the pathophysiology of psoriasis. In this study,
we have determined the expression pattern of components of the
calcineurin/NFAT signaling pathway in normal skin and psoriasis.
We also investigated whether CsA and tacrolimus inhibit activation
of calcineurin/NFAT in cultured human keratinocytes at thera-
peutically relevant doses.
MATERIALS AND METHODS
Materials CsA and tacrolimus were provided by Novartis Pharma
(Basle, Switzerland) and Fujisawa Pharmaceutical (Osaka, Japan),
respectively. Tacrolimus was also obtained from Af®nity Research
Products (Exeter, U.K.). Antibodies used were: rabbit polyclonal
antibody to cyclophilin A (Calbiochem-Novabiochem, Nottingham,
U.K.); murine monoclonal antibody to FKBP12 clone #2C1 (Dr.
Kobayashi, Fujisawa, Japan, and from PharMingen, CA); murine
monoclonal antibodies to calcineurin B (regulatory subunit) (Upstate
Biotechnology, NY), calcineurin A (catalytic subunit) (PharMingen),
CD1a (PharMingen), and rabbit polyclonal antibody to NFAT1 (Upstate
Biotechnology). HA-murine NFAT1 1-460-GFP (in pEGFP.N1) was a
kind gift from Dr. A Rao (Lopez-Rodriguez et al, 1999).
Western blotting Cells were lyzed in 2 3 sodium dodecyl sulfate
(SDS) sample buffer (125 mM Tris-HCl, pH 6.8, 0.05% bromophenyl
blue, 4% SDS, 20% glycerol, and 10% b-mercaptoethanol). Equal protein
quantities of samples and enhanced chemiluminescence molecular weight
markers (Amersham, Bucks, U.K.) were electrophoresed through 10%
polyacrylamide gels, and Western blotting was performed as described
previously (Todd and Reynolds, 1998), using anticyclophilin A (1:1000),
anti-FKBP12, anticalcineurin B (1:1000), or anti-NFAT1 (1:5000)
antibodies.
Subjects and skin biopsies The local Ethical Committee approved the
study protocol and all subjects gave written informed consent prior to
entering the study. Three normal volunteers (one male, two females,
mean age 41 y) and seven patients (®ve males, two females, mean age
36 y) with stable plaque psoriasis were initially recruited. Patients were
excluded if they had received systemic antipsoriatic, ultraviolet B, or
psoralen plus ultraviolet A therapy during the last 3 mo, or topical
medication, apart from emollients, during the last 2 wk. Paired 6 mm
punch biopsies were taken, under local anesthesia, from the edge of
psoriatic plaques (lesional) and nonlesional (uninvolved) skin (at least
2 cm from the edge of plaque) on the lower back/buttock, embedded in
optimal cutting temperature compound, frozen, and stored at ±70°C. For
the NFAT studies, skin biopsies were obtained from a further 12 patients
with psoriasis (seven males, ®ve females, mean age 48 y) and a further
eight normal volunteers (seven males, one female, mean age 21 y).
Immunohistochemistry of skin biopsies, cultured human
keratinocytes, and dermal ®broblasts Five micron frozen sections
of human skin were immunostained as described previously (Reynolds
et al, 1998) using antibodies to cyclophilin A (1:1500), FKBP12 (1:400),
calcineurin B (1:100), or NFAT1 (1:500), an avidin-biotin immuno-
peroxidase technique, and Ni-diaminobenzidine as the color substrate.
Sections were counterstained with methyl green. The degree of staining
was assessed on a semiquantitative scale (Reynolds et al, 1995) and the
predominant pattern of intracellular staining was assessed as cytoplasmic,
membranous, or nuclear. Blinding was not possible due to the
characteristic morphologic features of lesional psoriatic biopsies. For
double-labeling experiments, 5 mm frozen sections of human skin were
incubated sequentially with anti-CD1a antibody (1:10), biotinylated
horse antimouse IgG antibody (1:100), strepavidin Oregon Green 488
(Molecular Probes, OR) 1:100, anti-FKBP12 antibody (1:500), and
Alexa-568-labeled goat antimouse IgG (1:100) (Molecular Probes, OR).
Oregon Green 488 and Alexa 568 were excited using the 488 nm line
supplied by the Ar ion laser and the 543 nm line supplied by the HeNe
laser, respectively. Fluorescence emission was monitored line by line,
using the sequential scanning mode to minimize any possible crosstalk,
and Z series of images were captured using a Leica TCS SP II confocal
laser microscope (Leica Microsystems, Milton Keynes, U.K.).
Keratinocytes and ®broblasts were isolated from normal human skin
obtained from plastic and pediatric surgical procedures. Keratinocytes
Figure 1. Cyclophilin A, FKBP12, calcineurin
B, and NFAT1 are expressed by cultured
human keratinocytes. Cell lysates were prepared
from cultured keratinocytes, separated by SDS
polyacrylamide gel electrophoresis, and immuno
blotted with antibodies against cyclophilin A
(CyPA), calcineurin B (CaNB), FKBP12, or
NFAT1, as indicated. Results from two samples
derived from independent donors (lanes 1, 2) are
shown. The relative molecular mass of protein
markers is indicated to the left of the blots.
Figure 2. Localization of cyclophilin A, FKBP12, calcineurin B, and NFAT1 in normal human skin, lesional psoriatic skin, and
nonlesional psoriatic skin. (A) Frozen sections of normal human skin, lesional (plaque) psoriatic skin, and nonlesional (uninvolved) psoriatic skin
were immunostained with antibodies against cyclophilin A, calcineurin B, FKBP12, or NFAT1, as indicated. Ni-diaminobenzidine was used as the
chromagen (blue/black) and the sections were counterstained with methyl green. (B) Higher power view of NFAT1 immunostaining of normal human
skin, nonlesional psoriatic skin, and lesional psoriatic skin showing increased suprabasal nuclear NFAT1 localization in lesional and nonlesional psoriatic
skin compared to normal skin. Arrowheads indicate positive nuclear immunostaining. Nonimmune rabbit serum, at a similar dilution to NFAT1, was
included in the immunostaining protocol as a negative control. Methyl green counterstaining is seen but no signi®cant blue/black staining is present.
Scale bar: 50 mM.
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were cultured in T75 ¯asks in MCDB-153 (Sigma, Poole, U.K.) serum-
free medium with a calcium concentration of 70 mM, supplemented
with ethanolamine (6.1 ml per l), phosphoethanolamine (14 mg per ml),
hydrocortisone (0.18 mg per ml), insulin (5 mg per ml), transferrin (5 mg
per ml), epidermal growth factor (10 ng per ml), penicillin G (5 IU per
ml), streptomycin (5 mg per ml), and amino acids, essentially as described
previously (Todd and Reynolds, 1998). Keratinocytes were expanded by
serial passage and used for experiments between passages 2 and 3.
Fibroblasts were cultured in T75 ¯asks in Dulbecco's modi®ed Eagle's
medium (DMEM) with 10% fetal bovine serum (Sigma, Dorset, U.K.).
Cells were seeded onto glass coverslips, cultured until 50%±70%
con¯uent, and then treated with agonists as speci®ed. At de®ned time
points, cells were ®xed and permeabilized with 4% paraformaldehyde and
0.2% Triton X-100, and incubated sequentially with antibodies to
calcineurin A (1:100), calcineurin B (1:500), Oregon Green 488-labeled
or Alexa-568-labeled secondary antibodies (1:300) (Molecular Probes,
OR), and propidium iodide (50 mg per ml, Sigma). The number of cells
showing positive nuclear staining was counted under 603 magni®cation
using epi¯uorescence microscopy. In the studies on keratinocytes, a
minimum of 75 cells in three independent experiments (225 cells in
total) were assessed at each time point. Blinding was dif®cult due to the
characteristic morphologic features of cells treated with TPA or raised
extracellular calcium, but for the experiments examining the dosage
effects of CsA and tacrolimus, slides were coded and the observer was
masked from the treatment conditions. In the studies on ®broblasts, the
observer was again masked from the treatment conditions and a
minimum of 50 cells in three independent experiments (150 cells in
total) were assessed at each time point. Z series of images were captured
on a Biorad MRC 600 scanning laser confocal microscope (Bio-Rad
Laboratories, Herts, U.K.) with a Kr/Ar laser. Fluorescence emission of
Oregon Green, excited by the 488 nm laser line, and Alexa 568/
propidium iodide, excited by the 568 nm laser line, were captured
sequentially to minimize crosstalk.
Images were processed using Confocal Assistant (Version 4.02, Todd
Clark Brelje) and Adobe Photoshop (San Jose, CA). Mid-cell image
sections are shown. Isotype IgG or polyclonal rabbit serum were included
at equivalent concentrations to the primary antibodies in immunohisto-
chemical and immuno¯uorescence studies as negative controls.
Transfection of epidermal human keratinocytes Three 3 104
keratinocytes were seeded onto 22 mm2 sterile coverslips and cultured
until approximately 60%±70% con¯uent. Cells were then switched to
antibiotic-free medium and transfected with HA-NFAT1-GFP or
pEGFP.N1 (Clontech, Hampshire, U.K.) using Lipofectamine Plus
(Gibco BRL Life Technologies, Paisley, U.K.), according to the
manufacturer's instructions. In brief, for each coverslip, 2 mg of DNA
and 6 ml of Plus reagent were diluted in serum-free, antibiotic-free
MCDB-153 medium and incubated for 15 min at room temperature.
Pre-complexed DNA and 4 ml of diluted Lipofectamine were combined,
incubated for 15 min, and then added to cells for 3 h at 37°C. To
maximize cell growth, medium was then replaced with fresh serum-free,
antibiotic-free medium MCDB-153. After 24 h, transfected cells were
transferred to a temperature-controlled perfusion chamber (Intracel,
Royston, U.K.), maintained at 37°C, and visualized following excitation
of green ¯uorescent protein by the 488 nm laser line using a Leica TCS
SP II confocal laser microscope (Leica Microsystems).
Statistical analysis To compare the effect of speci®ed treatments on
the number of cells showing positive nuclear immunostaining, c2 analysis
was used. To assess the dosage effects of CsA on NFAT1 translocation,
c2 analysis of trend was performed. Fisher's exact test was used to
compare the proportion of subjects showing nuclear immunostaining of
NFAT1 in basal and suprabasal keratinocytes. Data were analyzed using
Arcus Quickstat (Biomedical Version 1.0).
RESULTS
Cyclophilin A, FKBP12, calcineurin, and NFAT1 are
coexpressed in cultured human keratinocytes and in
normal and psoriatic skin in vivo Western blotting showed
that cultured human keratinocytes coexpress cyclophilin A,
FKBP12, calcineurin B, and NFAT1 (Fig 1). These experiments
demonstrated that the antibodies detect appropriate molecular
weight proteins in skin cells (»18 kDa for cyclophilin A, »12 kDa
for FKBP12, »19 kDa for calcineurin B, and »130 kDa for
NFAT1) and do not signi®cantly crossreact with other proteins in
these cell lysates.
Immunohistochemical studies of normal human and psoriatic skin
showed prominent expression of cyclophilin A, FKBP12, calcineur-
in B, and NFAT1 in epidermal keratinocytes (Fig 2A) together with
expression in dermal ®broblasts. Langerhans cells within the
epidermis also expressed cyclophilin A, FKBP12, and calcineurin
B in normal and psoriatic skin (Fig 3). Calcineurin B and NFAT1
immunostaining was also observed in vascular endothelial cells, skin
appendages, and within the dermal in¯ammatory cell in®ltrate in
psoriasis (Fig 2A). High levels of cyclophilin A expression were
observed within the cytoplasm of basal epidermal keratinocytes,
with reduced levels within the more differentiated, suprabasal cells
(Fig 2A). Cytoplasmic and membrane patterns of calcineurin B
expression were observed in keratinocytes (Fig 2A). In contrast to
cyclophilin A and calcineurin B, FKBP12 showed nuclear localiza-
tion in epidermal keratinocytes and dermal ®broblasts, and, within
epidermis, expression appeared reduced in high suprabasal kerati-
nocytes (Fig 2A). No consistent differences were observed between
normal skin, lesional psoriatic skin, or nonlesional psoriatic skin with
respect to cyclophilin A, FKBP12, and calcineurin expression
(Fig 2A). NFAT1 showed cytoplasmic and nuclear localization in
epidermal keratinocytes. As a negative control, nonimmune rabbit
serum at a similar dilution to NFAT1 was included in the
immunostaining protocol and showed no positive immunoreactivity
(Fig 2B). NFAT1 appeared predominantly nuclear in normal basal
keratinocytes but showed reduced nuclear and increased cytoplasmic
expression in differentiating suprabasal cells (Fig 2A, B). Increased
nuclear immunostaining in suprabasal keratinocytes was observed in
lesional and to a lesser extent in nonlesional psoriatic skin compared
to normal controls (Fig 2A, B). The proportion of subjects showing
predominantly nuclear-associated NFAT1 immunostaining in
suprabasal keratinocytes was signi®cantly increased in lesional
psoriatic skin biopsies (12 of 12, p = 0.001) and nonlesional psoriatic
skin biopsies (8 of 12, p = 0.03) compared to normal skin (1 out of 8).
Nuclear translocation of NFAT1 in human keratinocytes is
inhibited by CsA and tacrolimus As calcineurin activation in
T cells results in translocation of NFAT1 and calcineurin to the
nucleus (Rao et al, 1997), we next studied the intracellular
distribution of the NFAT1 and calcineurin in cultured
keratinocytes to determine whether this pathway is functionally
active in these cells. In untreated keratinocytes or cells treated with
vehicle, NFAT1 was found predominately in the cytoplasm
(Fig 4A) (8.8% and 16.0% nuclear positivity, respectively; n =
225 cells) (Fig 5A). Because activation of calcineurin requires a
sustained rise in intracellular calcium and CsA inhibits TPA-
induced changes in mouse skin (Reynolds et al, 1998), we initially
treated cultured human keratinocytes with TPA (50 nM) plus
ionomycin (1 mM), agonists that induce keratinocyte differenti-
ation (Zhao et al, 1992). We found increased nuclear localization of
NFAT1 by 15 min (58.4% nuclear positivity), which was maximal
at 4 h (84.4% nuclear positivity) and persisted to 18 h (81.8%
nuclear positivity) (n = 225 cells) (Figs 4A, 5A). TPA (50 nM)
alone or increasing extracellular calcium ([Ca2+]o) from 70 mM to
1.5 mM also cause a rise in intracellular calcium (Sharpe et al, 1993)
and induce keratinocyte differentiation, and both these agonists
resulted in increased nuclear localization of NFAT1 (Fig 4A) with
similar kinetics to TPA plus ionomycin (Fig 5A).
To con®rm that our assessment of NFAT1 subcellular localiz-
ation by immuno¯uorescence had not been affected by ®xation and
to further validate the speci®city of the NFAT1 antibody that we
had utilized, we transfected keratinocytes with HA-NFAT1-GFP,
examined the cellular localization of HA-NFAT1-GFP by confocal
microscopy, and monitored single cells in real time. These studies
showed that HA-NFAT1-GFP was predominantly localized to the
cytoplasm in untreated keratinocytes (Fig 6) and showed a similar
distribution to endogenous NFAT1 detected by immuno¯uores-
cence (Fig 4A). Treatment with TPA (50 nM) plus ionomycin
(1 mM) for 1 h resulted in translocation of HA-NFAT1-GFP to the
nucleus (Fig 6). Similar responses were observed following treat-
ment of keratinocytes, transfected with HA-NFAT1-GFP, with
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Figure 3. Langerhans cells in human skin express cyclophilin A, FKBP12, and calcineurin B. (A) Cyclophilin A immunostaining of normal
human skin. (B) Calcineurin B immunostaining of nonlesional psoriatic skin. Expression of cyclophilin A (A) and calcineurin B (B) by Langerhans cells
is indicated by arrows. (C), (D), (E) Double-labeling of normal human skin with antibodies to CD1a (Oregon Green 488) (C) and FKBP12 (Alexa 568)
(D), visualized by scanning confocal microscopy. Images were overlayed (E). Colocalization of CD1a and FKBP12 appears yellow and is indicated by
arrows. The position of the epidermal±dermal junction is indicated by the dashed line. Mid-section images are shown. Scale bar: 50 mM.
Figure 4. Nuclear translocation of NFAT1 (A) and calcineurin A and calcineurin B (B) in human keratinocytes is inhibited by
cyclosporin A. Human keratinocytes were cultured on coverslips in low calcium MCDB-153 medium (control) and then treated with dimethyl
sulfoxide (DMSO) (vehicle control) or TPA (50 nM) plus ionomycin (1 mM) or ­[Ca2+]o (raised extracellular calcium, 1.5 mM) for 4 h. Some
coverslip cultures were pretreated with cyclosporin A (CsA) 1 mM for 1 h, as indicated. Cells were ®xed in 4% paraformaldehyde and permeabilized
with 0.2% Triton X-100. Immuno¯uorescence labeling was performed as described in Materials and Methods. In (A) cells were labeled with anti-NFAT1
antibody (Oregon Green 488) and propidium iodide (PI) and in (B) cells were double-labeled with anticalcineurin B (Alexa 568), and anticalcineurin A
(Oregon Green 488). Cells were then visualized using confocal microscopy. The images shown are mid-cell sections. These results are representative of
three experiments on keratinocytes derived from three independent donors. Scale bar: 25 mM.
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TPA and raised extracellular calcium (1.5 mM) (data not shown).
The empty GFP vector was distributed evenly throughout the cell
and there was no change in its cellular location following treatment
of keratinocytes with TPA plus ionomycin, TPA, or raised
extracellular calcium (data not shown).
We next determined whether CsA and tacrolimus inhibited
translocation of endogenous NFAT1 in human keratinocytes. We
found that CsA (1 mM) and tacrolimus (1 mM) signi®cantly
inhibited nuclear translocation of NFAT1 induced by TPA plus
ionomycin, TPA, and increased extracellular calcium at 4 h
(Fig 4A and Table I). The comparisons of the data presented in
Table I re¯ect the structure of the data and the hypotheses being
tested. In further experiments, we assessed the effects of a range of
CsA and tacrolimus doses (1 nM, 10 nM, 100 nM, and 1 mM) on
NFAT1 nuclear translocation. The data in Table II show that
100 nM CsA and 100 nM tacrolimus inhibited nuclear trans-
location of NFAT1 induced by TPA/ionomycin and TPA by
approximately a third but did not appear to affect nuclear
translocation of NFAT1 induced by increased extracellular calcium.
Analysis of trend indicates a signi®cant dosage effect for both CsA
and tacrolimus on nuclear translocation of NFAT1 induced by
TPA/ionomycin (p < 0.0001), TPA (p < 0.0001), and increased
extracellular calcium (p < 0.0001).
Translocation of calcineurin to the nucleus and plasma
membrane in human keratinocytes is inhibited by CsA and
tacrolimus Comigration of calcineurin to the nucleus is required
to maintain NFAT in a dephosphorylated state, prevent export of
NFAT from the nucleus, and sustain activation of NFAT target
genes (Shibasaki et al, 1996; Zhu and McKeon, 1999). We
therefore investigated whether nuclear translocation of NFAT1 was
accompanied by comigration of calcineurin A and B subunits in
human keratinocytes. Figure 4(B) shows that TPA, TPA plus
ionomycin, and increased extracellular calcium induced trans-
location of calcineurin A and B to the nucleus. The time course of
calcineurin nuclear translocation (Fig 5B) appeared to lag slightly
behind that for NFAT1 (Fig 5A). For example, in cells treated
with TPA plus ionomycin, we observed 4% nuclear positivity at
15 min that increased to 15.3% at 2 h but was not maximal until
18 h (88.7% nuclear positivity) (n = 225 cells). In cells exposed to
TPA or raised extracellular calcium, the time course of increasing
calcineurin nuclear positivity were similar up to 4 h. In cells
exposed to raised extracellular calcium, however, the degree of
nuclear-associated calcineurin had returned towards baseline by
18 h, in contrast to cells treated with TPA or TPA plus ionomycin
(Fig 5B). CsA (1 mM) inhibited nuclear translocation of
calcineurin A and B at 4 h (Fig 4B, Table I). In separate experi-
ments, tacrolimus also inhibited nuclear translocation of calcineurin
A and B at 4 h (data not shown). We observed increased association
of calcineurin A and B with the plasma membrane, most marked at
4 h, following treatment with TPA plus ionomycin, TPA, and
increased extracellular calcium, which was inhibited by
pretreatment with CsA (Fig 4B). In addition, CsA inhibited the
shape change and ¯attening of keratinocytes that occurred in
response to increased extracellular calcium at 4 h (Fig 4B).
TPA plus ionomycin or TPA do not induce nuclear
translocation of NFAT1 in human dermal ®broblasts In
order to assess whether activation of calcineurin/NFAT in human
skin was dependent on cellular context, we investigated NFAT1
nuclear localization in cultured human dermal ®broblasts. In
contrast to human keratinocytes, NFAT1 appeared evenly
distributed between the cytoplasm and nucleus in unstimulated
cells (Fig 7). Furthermore, treatment of ®broblasts with TPA plus
ionomycin or TPA for between 2 h and 18 h did not signi®cantly
alter the cellular distribution of NFAT1 or the proportion of cells
showing nuclear NFAT1 positivity (Fig 7 and Table III). We
next determined the effect of CsA (1 mM) or tacrolimus (1 mM) on
NFAT1 localization in these cells. CsA (1 mM) for 2 h or 4 h did
not signi®cantly alter the proportion of ®broblasts displaying
NFAT1-immunostained nuclei (Table III, Fig 7). Treatment of
®broblasts with CsA (1 mM) for 18 h, however, reduced the
percentage of NFAT1 positively immunostained nuclei nuclear
from 97% to 83% (p < 0.0001). Tacrolimus for 2 h reduced the
percentage of NFAT1 positively immunostained nuclei nuclear
from 97% to 91% (p = 0.03) (Fig 7, Table III) but no signi®cant
effect was observed at 4 h or 18 h. Overall, the effects of CsA and
tacrolimus appeared less compared to equivalent doses in
keratinocytes and showed kinetic differences. These data indicate
that dermal ®broblasts and keratinocytes show distinct differences in
Figure 5. Time course of NFAT1 (A) and calcineurin B (B)
nuclear translocation in human keratinocytes in response to TPA
(50 nM), TPA plus ionomycin (1 mM), and raised extracellular
calcium ([Ca2+]o, 1.5 mM). Human keratinocytes were cultured on
coverslips and immunostained as described in the legend to Fig 3. The
number of cells showing positive nuclear staining was counted using
epi¯uorescence microscopy. At least 225 cells from three independent
experiments were assessed at each time point.
Figure 6. Translocation of NFAT1-GFP in human keratinocytes.
Human keratinocytes were cultured on coverslips in low calcium
MCDB-153 medium and then transfected with HA-NFAT1-GFP.
Twenty-four hours later cells were visualized by confocal microscopy (A)
and then treated with TPA (50 nM) plus ionomycin (1 mM) at 37°C.
Re-scanning of the same cell after 1 h (B) showed translocation of HA-
NFAT1-GFP to the nucleus. Scale bar: 20 mM.
784 AL-DARAJI ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
their activation pattern of calcineurin/NFAT1 and differ in their
responsiveness to CsA and tacrolimus.
DISCUSSION
These studies show for the ®rst time that nonimmune cells in
normal and psoriatic skin express the key components of the
calcineurin/NFAT signal transduction pathway, speci®cally the
principal CsA and tacrolimus binding proteins cyclophilin A and
FKBP12, respectively, the phosphatase calcineurin, and the tran-
scription factor NFAT1, that mediate downstream signaling of CsA
and tacrolimus in T cells. Expression of all four proteins was
prominent in keratinocytes. Langerhans cells also expressed
cyclophilin A, FKBP12, and calcineurin B. As nuclear localization
of NFAT provides evidence of calcineurin activation (Kiani et al,
2000), our observation of increased nuclear localization of NFAT1
in suprabasal keratinocytes of psoriatic epidermis is particularly
interesting. Our studies of primary cultured keratinocytes provide
the ®rst description of the subcellular localization of endogenous
calcineurin A, calcineurin B, and NFAT1 in these cells.
Furthermore, we have shown that calcineurin is functionally active
in human keratinocytes by demonstrating nuclear translocation of
endogenous NFAT1 in response to differentiation stimuli that is
inhibited by CsA and tacrolimus in a dose-dependent manner, at
therapeutically relevant doses (Ellis et al, 1991; Cooper et al, 1992).
Recently, Nishio et al have also reported immunolocalization of
calcineurin and FKBP12 in normal human epidermal keratinocytes
(Nishio et al, 2000). Taken together, these data identify a potential
local, T-cell-independent, mechanism of action for CsA and
tacrolimus in psoriasis that may contribute, at least in part, to the
therapeutic effects of these drugs.
Topical CsA is ineffective in psoriasis as it is not absorbed,
although intralesional CsA improves psoriasis (Burns et al, 1992).
Tacrolimus is a smaller molecule that is able to induce clearance of
psoriasis following topical application under occlusion (Remitz et al,
1999). Systemic CsA rapidly inhibits epidermal IL-1 and IL-8
expression in psoriatic skin, prior to clinical improvement (Prens et al,
1995), suggesting that modulation of the keratinocyte cytokine
network may play a role in the therapeutic effect of CsA in psoriasis.
Further work is required, however, to dissect the relative contri-
bution of inhibiting NFAT pathways in lymphocytes, Langerhans
cells, and keratinocytes to the therapeutic effect of CsA and
tacrolimus in psoriasis. Although T cells have been implicated in the
pathogenesis of psoriasis, certain clinical patterns, such as a linear
form occurring in Blaschko's lines suggesting genetic mosaicism or
some epigenetic change in epidermis (Happle, 1991), an increased
rate of keratinocyte proliferation in uninvolved psoriatic skin
compared to normal skin, and hyperresponsiveness of uninvolved
psoriatic skin to proliferation stimuli (Wiley and Weinstein, 1979),
remain, however, hard to explain, on the basis of a T-cell-driven
process alone. Furthermore, supernatants from T cells cloned from
psoriatic plaques stimulated proliferation of ``stem cells'' from
nonlesional psoriatic skin but not stem cells from normal skin (Bata-
Csorgo et al, 1995), suggesting an intrinsic difference between
psoriatic and normal keratinocytes. Moreover, therapeutic agents
targeted to interfere speci®cally with T cell function (including the
fusion protein DAB389IL-2, the soluble chimeric protein cytotoxic
T-lymphocyte-associated antigen-4[CTLA-4], humanized anti-
CD4 monoclonal antibody, and a humanized monoclonal antibody
to CD11a) show variable ef®cacy as antipsoriatic treatments (Bagel et
al, 1998; Abrams et al, 1999; Gottlieb et al, 2000a, b) and appear only
partially effective when assessed in randomized controlled trials
(Bagel et al, 1998; Gottlieb et al, 2000a, b). Although a partial clinical
response may represent incomplete blockade of T cell function, an
alternative explanation is that inhibition of keratinocyte activation is
also required for clearance of psoriasis.
The family of NFAT nuclear transcription factors comprises ®ve
members with alternative splicing resulting in several isoforms.
NFAT1, NFAT2, NFAT3, and NFAT4 are structurally and
functionally related and undergo translocation to the nucleus
following dephosphorylation by calcineurin (Rao et al, 1997;
Kiani et al, 2000). NFAT family members display unique and
relatively narrow tissue patterns of protein expression (Rao et al,
1997; Kiani et al, 2000) and show temporal regulation of expression
during embryogenesis. For example, NFAT1 protein is present in
lymphocytes, lymphoid organs (thymus and spleen), olfactory
epithelium, endothelial cells, but not in small intestine, liver,
kidney, cardiac, or skeletal muscle (Wang et al, 1995; Rao et al,
1997); NFAT4 is highly expressed in thymocytes and smooth muscle
Table I. Induction of NFAT1 and calcineurin B nuclear translocation in human keratinocytes and inhibition by











Medium controla 8.8 225 2.3 255
DMSO controlb 16.0 225 1.8 275
TPA/ionomycinc 84.4h 225 73.3h 289
CsAd then TPA/ionomycin 22.6i 225 7.3i 300
Tacrolimuse then TPA/ionomycin 51.3i 225 ± ±
TPAf 76.4h 225 60.7h 286
CsAd then TPA 11.0j 225 8.7j 300
Tacrolimuse then TPA 33.7j 225 ± ±
Increased [Ca2+]o
g 85.6k 225 95k 395
CsAd then increased [Ca2+]o 38.0
l 225 8.7l 300
Tacrolimuse then increased [Ca2+lus;]o 47.0
l 225 ± ±
aLow calcium (70 mM) medium.
bVehicle control.
cTPA (50 nM) plus ionomycin (1 mM).
dPretreatment with CsA (1 mM) for 1 h.
ePretreatment with tacrolimus (1 mM) for 1 h.
fTPA (50 nM).
gRaised extracellular calcium (1.5 mM).
hp < 0.0001 compared to DMSO control.
ip < 0.0001 compared to TPA/ionomycin.
jp < 0.0001 compared to TPA.
kp < 0.0001 compared to medium control.
lp < 0.0001 compared to increased [Ca2+]o.
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(Oukka et al, 1998; Stevenson et al, 2001); and transient expression of
NFAT2 within the nuclei of endocardial cells is required for heart
valve formation during embryogenesis (de la Pompa et al, 1998;
Ranger et al, 1998). NFAT binds only weakly to DNA and requires a
partner protein (e.g., AP1 or GATA4), which varies among cell
types, in order to initiate transciptional activation (Crabtree, 1999).
In addition, distinctive mechanisms of nuclear localization among
NFAT family members have been identi®ed (Graef et al, 1999).
Therefore a number of independent mechanisms may contribute to
the tissue and cellular speci®city of responses.
As NFAT1 mRNA is detectable in mouse skin (Northrop et al,
1994), we focused our initial studies on NFAT1, but we have also
detected mRNA for NFAT2, NFAT3, and NFAT4 in cultured
human keratinocytes (unpublished observations). The function of
calcineurin/NFAT in human skin is currently unknown.
Activation of calcineurin/NFAT by TPA, TPA and ionomycin,
and raised extracellular calcium, however, suggests that this
pathway plays a role in regulating keratinocyte differentiation.
Santini et al have very recently shown that calcineurin regulates the
expression of mouse keratinocyte differentiation markers and the
cyclin-dependent kinase inhibitor p21WAF1 through a mechanism
that appears to involve an interaction between NFAT1/NFAT2
and the Sp1/Sp3 transcription factors (Santini et al, 2001). Nuclear
localization of NFAT provides evidence of calcineurin activation,
and furthermore, the proportion of NFAT in the nucleus is
thought to be a re¯ection of the overall level of calcineurin activity
(Kiani et al, 2000). Increased nuclear NFAT1 in psoriatic skin may
therefore account for the increased suprabasal expression of
p21WAF1 observed in psoriasis (Healy et al, 1995), although the
absence of ®laggrin expression in psoriatic plaques (Bernard et al,
1988) is not readily explained. Previous work in BHK ®broblasts
has indicated that comigration of calcineurin to the nucleus is
required to maintain GFP-NFAT4 in the nucleus and prevent its
export (Shibasaki et al, 1996; Zhu and McKeon, 1999). In contrast,
our time course studies of endogenous calcineurin and NFAT1
suggest that nuclear translocation of calcineurin lags slightly behind
that of NFAT1. Furthermore, although the degree of calcineurin
nuclear positivity had returned towards baseline following exposure
to raised extracellular calcium for 18 h, NFAT1 nuclear positivity
was maintained at this time point. Our studies of calcineurin and
NFAT1, however, were performed on keratinocytes derived from
different donors. Further work utilizing, for example, GFP-tagged
proteins is therefore required to con®rm these results and we are in
the process of preparing the appropriate constructs.
Sustained mobilization of calcium is required for activation of
NFAT. The recent studies of NFAT4 in mouse smooth muscle
cells by Stevenson et al, however, indicate that prolonged elevation
of intracellular calcium may not be suf®cient (Stevenson et al, 2001)
and that the calcium signaling mechanisms involved in activating
NFAT are cell type speci®c. Within the basal layer, calcium is
localized primarily to mitochondria and the nucleus; more
abundant intracellular deposits are found in upper epidermal layers
and calcium is thought to regulate both keratinocyte growth and
differentiation (Menon and Elias, 1991), although the mechanisms
involved are not well understood. Increased calcium within the
cytosolic and nuclear compartments of keratinocytes (Menon and
Elias, 1991) and increased calmodulin activity (Tucker et al, 1984;
Mizumoto et al, 1985) in psoriatic epidermis may contribute to
calcineurin activation and increased nuclear localization of NFAT1
in psoriatic skin. Our studies in cultured keratinocytes have shown
that TPA plus ionomycin and raised extracellular calcium, agents
that induce sustained rises in intracellular calcium, result in
translocation of NFAT1 and calcineurin to the nucleus, which is
inhibited by CsA and tacrolimus. Induction of nuclear translocation
of NFAT1 by TPA alone has not been observed in other cell types,
although in human keratinocytes prolonged treatment with TPA
leads to a sustained rise of intracellular calcium (Sharpe et al, 1989)
and terminal differentiation. Although NFAT1 is also expressed by
human dermal ®broblasts, we did not observe translocation of
NFAT1 to the nucleus upon stimulation with TPA or TPA plus
ionomycin. Furthermore, the in¯uence of CsA and tacrolimus on
the proportion of NFAT1 localized to the nucleus in human
®broblasts was less marked than in keratinocytes. These data
underscore that the responsiveness and regulation of the calci-
neurin/NFAT pathway in human skin is cell type speci®c. The
functional consequences of NFAT activation in skin remain to be
fully explored, but genes expressed by keratinocytes and known to
be regulated by NFAT include granulocyte macrophage colony
stimulating factor, tumor necrosis factor a, FasL, and intercellular
adhesion molecule 1 (Kiani et al, 2000).
The intracellular distribution of cyclophilin A, FKBP12, and
calcineurin B varies among cell types. For example, calcineurin B
was found predominantly in the cytosolic fraction in human T cells
(Le Hir et al, 1995), whereas in brain a signi®cant portion was
located in the membrane fraction (Klee et al, 1988). We found that
localization of calcineurin B to the keratinocyte cell membrane was
a prominent feature in sections of normal and psoriatic skin and we
observed translocation of calcineurin B to the plasma membrane in
response to agonists that induce a rise in intracellular calcium.
Distinct mechanisms regulate targeting of calcineurin to speci®c
cellular locations and substrates. Although the mechanisms regu-
lating targeting of calcineurin to the plasma membrane are not well
understood, calcineurin B contains a myristoylation signal (Klee et
al, 1988) and calcineurin A binds to the anchoring protein AKAP79
Table II. Inhibition of NFAT1 nuclear translocation by











Medium controla 15.1 225
DMSO controlb 18.2 225
TPA/ionomycinc 91.1 225
CsAd 1 nM then TPA/ionomycinc 81.8 225
CsAd 10 nM then TPA/ionomycinc 82.2 225
CsAd 100 nM then TPA/ionomycinc 66.2 225
CsAd 1 mM then TPA/ionomycinc 29.8 225
Tacrolimuse 1 nM then TPA/ionomycinc 88.4 225
Tacrolimuse 10 nM then TPA/ionomycinc 86.2 225
Tacrolimuse 100 nM then TPA/ionomycinc 60.9 225
Tacrolimuse 1 mM then TPA/ionomycinc 56.0 225
TPAf 79.1 225
CsAd 1 nM then TPAf 77.3 225
CsAd 10 nM then TPAf 54.2 225
CsAd 100 nM then TPAf 55.6 225
CsAd 1 mM then TPAf 20.4 225
Tacrolimuse 1 nM then TPAf 81.3 225
Tacrolimuse 10 nM then TPAf 76.0 225
Tacrolimuse 100 nM then TPAf 68.4 225
Tacrolimuse 1 mM then TPAf 45.8 225
Increased [Ca2+]o
g 87.1 225
CsAd 1 nM then increased [Ca2+]o
g 77.3 225
CsAd 10 nM then increased [Ca2+]o
g 72.9 225
CsAd 100 nM then increased [Ca2+]o
g 74.7 225
CsAd 1 mM then increased [Ca2+]og 40.9 225
Tacrolimuse 1 nM then increased [Ca2+]o
g 72.9 225
Tacrolimuse 10 nM then increased [Ca2+]o
g 72.9 225
Tacrolimuse 100 nM then increased [Ca2+]o
g 63.1 225
Tacrolimuse 1 mM then increased [Ca2+]og 48.4 225
aLow calcium (70 mM) medium.
bVehicle control.
cTPA (50 nM) plus ionomycin (1 mM).
dPretreatment with CsA for 1 h.
ePretreatment with tacrolimus for 1 h.
fTPA (50 nM).
gRaised extracellular calcium (1.5 mM).
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that attaches to the plasma membrane (Aramburu et al, 2000). In
contrast to calcineurin B, FKBP12 was predominantly localized to
the nucleus in epidermal keratinocytes and dermal ®broblasts.
Nuclear localization of FKBP12 has been described in human
mononuclear cells and in T cells by immunostaining and Western
analysis (Kobayashi et al, 1993; Le Hir et al, 1995). Interestingly,
alteration in nuclear localization and intracellular distribution of
FKBP12 was observed in mononuclear cells and in Jurkat T cells
following stimulation and serum deprivation (Kobayashi et al,
1993). Variation in the subcellular distribution and level expression
of immunophilins and calcineurin in different cell types may
contribute to the diversity of functional effects among tissues in
response to CsA and tacrolimus. Although calcineurin appears to be
expressed in most tissues studied, the level of expression varies
signi®cantly among tissues (Crabtree, 1999). Evidence indicates
that the response of different cells and tissues to CsA and tacrolimus
depends on the level of calcineurin expressed and is less in cells
expressing high levels of calcineurin (Crabtree, 1999).
There is concern about the long-term side-effects, particularly
nephrotoxicity, from the use of systemic CsA and tacrolimus for
treating psoriasis (Powles et al, 1998). Although the mechanism of
renal damage remains to be fully de®ned, inhibition of calcineurin
activity in the kidney is thought to play an important role (Tumlin,
1997). If these drugs are exerting important therapeutic effects
locally in skin through inhibition of NFAT activation, optimization
of topical delivery or development of topical drugs that speci®cally
target NFAT may result in important therapeutic advances.
Figure 7. TPA and ionomycin do not induce
nuclear translocation of NFAT1 in human
dermal ®broblasts. Human dermal ®broblasts
were cultured on coverslips in DMEM and 10%
fetal bovine serum and then treated with DMSO
(vehicle control), TPA (50 nM) plus ionomycin
(1 mM), ionomycin (1 mM), CsA (1 mM), or
tacrolimus (1 mM) for the indicated times. Cells
were ®xed in 4% paraformaldehyde and
permeabilized with 0.2% Triton X-100. Immuno-
¯uorescence labeling was performed with anti-
NFAT1 antibody (Oregon Green 488) and
propidium iodide (PI) as described in Materials and
Methods. Cells were then visualized using confocal
microscopy. These results are representative of
three experiments on ®broblasts derived from
three independent donors. Scale bar: 25 mM.








Medium controla 94.0 150
DMSO controlb 97.3 150
TPA/ionomycinc 2 h 97.3 150
TPA/ionomycinc 4 h 97.3 150
TPA/ionomycinc 18 h 99.3 150
TPA 50 nM 2 h 97.3 150
TPA 50 nM 4 h 98.0 150
TPA 50 nM 18 h 96.0 150
CsA 1 mM 2 h 94.0 150
CsA 1 mM 4 h 94.0 150
CsA 1 mM 18 h 83.3d 150
Tacrolimus 1 mM 2 h 90.7e 150
Tacrolimus 1 mM 4 h 92.7 150
Tacrolimus 1 mM 18 h 96.7 150
aDMEM plus 10% fetal bovine serum.
bVehicle control.
cTPA (50 nM) plus ionomycin (1 mM).
dp < 0.0001 compared to DMSO control.
ep = 0.03 compared to DMSO control.
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